Knockout targets vasculogenic mimicry in pancreatic cancer, suggesting new therapeutic strategies.
Pancreatic ductal adenocarcinoma (PDA) remains largely refractory to anti-angiogenic strategies, and non-endothelial perfusion mechanisms such as vasculogenic mimicry (VM, endothelial-like channels formed by tumour cells) may sustain tumour progression. Here, we examined whether the combined knockout of p21-activated kinase 1 and 4 (PAK1&4) affects vascular mimicry (VM) programmes in pancreatic cancer. KPC wild-type or PAK1&4 knockout cells were injected subcutaneously into immunodeficient mice. Knockout of PAK1& 4 suppressed tumour growth, associated with VM inhibition, but not endothelial angiogenesis. Knockout of PAK1& 4 reduced tumour expression of VM markers EphA2, VE-cadherin and MCAM, and decreased EphA2⁺VE-cadherin⁺ and EphA2⁺MCAM⁺, CD31+VE-cadherin+ and CD31+MCAM+ cells. In vitro, PAK1 knockout and PAK1& 4 knockout suppressed VM-like tube formation and migration, whereas PAK4 knockout enhanced tube formation. Global proteomics linked PAK1 knockout to downregulation of EPH–Ephrin signalling and reduced EphA2–MCAM–RhoA abundance, while PAK4 knockout enriched blood-vessel morphogenesis molecules. These findings identify a PAK-dependent VM programme and suggest that dual PAK targeting inhibits tumour growth by VM inhibition.
No takes yet. Share an insight, caveat, or question.
Ansardamavandi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: